RTI-101试验失败后，蒂瓦尔迪在雷蒙德·詹姆斯的评级被降级

2025-10-14 22:50

Raymond James downgraded Tivardi Therapeutics (NASDAQ:TVRD) to market perform from outperform citing the recent disappointing phase 2 data release of TTI-101 for idiopathic pulmonary fibrosis.
The investment firm pulled its price target.
Analyst Ryan Deschner said that questions surrounding TTI-101's viability remain considering the high number of discontinuations in the active treatment arms of the trial and whether the drug actually slows lung fibrosis in IPF patients.
He added that while Tivardi has topline phase 2 data on TTI-101 in liver cancer due in H1 2026 to look forward to and earlier findings in this indication were encouraging, "we see the discontinuation rate seen in [the] readout as added risk to this program. Given the aggregate of these dynamics, as well as the removal of the IPF opportunity from our model, we are downgrading..."

More on Tvardi Therapeutics